Copyright
©The Author(s) 2015.
World J Gastroenterol. Nov 28, 2015; 21(44): 12558-12575
Published online Nov 28, 2015. doi: 10.3748/wjg.v21.i44.12558
Published online Nov 28, 2015. doi: 10.3748/wjg.v21.i44.12558
Table 5 Nucleoside analogs in development for hepatitis B virus
| Name | MOA | Developed by | Phase |
| Clevudine | DNA polymerase inhibition | Bukwang Pharmaceutical, South Korea | Approved in South Korea and Philippines |
| Besifovir | DNA polymerase inhibition (pro-drug) | Ildong Pharmaceuticals and LG Life Sciences | Phase III |
| Tenofoviralafenamide | DNA polymerase inhibition (pro-drug) | Gilead Sciences, United States | Phase III |
| CMX157 | DNA polymerase inhibition (pro-drug) | ContraVir Pharmaceuticals, United States | Phase III |
| AGX-1009 | DNA polymerase inhibition (pro-drug) | Agenix, Australia | Phase I |
- Citation: Manzoor S, Saalim M, Imran M, Resham S, Ashraf J. Hepatitis B virus therapy: What’s the future holding for us? World J Gastroenterol 2015; 21(44): 12558-12575
- URL: https://www.wjgnet.com/1007-9327/full/v21/i44/12558.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i44.12558